Introduction {#section5-1756283X16673556}
============

Colonoscopy (CS) is a gold standard for the diagnosis of colorectal diseases such as colorectal cancer or inflammatory bowel disease. However, it is difficult to perform complete CS in some patients, and others hesitate to undergo CS. The cecal intubation rates on CS are reportedly 85-- 95% \[[@bibr2-1756283X16673556]; [@bibr22-1756283X16673556]; [@bibr1-1756283X16673556]; [@bibr16-1756283X16673556]; [@bibr5-1756283X16673556]; [@bibr8-1756283X16673556]\], and other procedures will be suggested in patients with incomplete CS.

Colon capsule endoscopy (CCE) is a procedure in which capsule swallowing facilitates observation of the lumen of the entire digestive tract. It does not require an air supply, and is a noninvasive procedure with a markedly low risk of adverse events in comparison with conventional CS. It reduces patient stress, and may be acceptable to patients \[[@bibr20-1756283X16673556]\].

Another option of colorectal examination is computerized tomography (CT) colonography (CTC). The sensitivity and specificity of CTC is high in the diagnostic yield of colorectal polyps, suggesting the usefulness of CTC \[[@bibr14-1756283X16673556]; [@bibr9-1756283X16673556]; [@bibr18-1756283X16673556]\]. On the other hand, a study indicated that the sensitivity and specificity of CCE for colorectal polyp detection were favorable in patients with incomplete CS, and that the colorectal polyp detection rate was higher than that of CTC \[[@bibr25-1756283X16673556]\]. As such, demands for CCE have been increasing and the role of CCE will become more important in the future.

However, issues to be clinically resolved have been raised: the entire colon observation rate on CCE (excretion rate, completed CCE rate) is not 100%. According to previous clinical studies, the rate ranges from 70--90% \[[@bibr6-1756283X16673556]; [@bibr21-1756283X16673556]; [@bibr29-1756283X16673556]; [@bibr13-1756283X16673556]; [@bibr26-1756283X16673556]\]. To improve the excretion rate, preparation regimens have been discussed. However, no clinical study has been conducted into the types of patient that can complete CCE. In other words, factors influencing complete CCE have not been reviewed. It is essential to select the patient who is suitable for CCE.

Even CS could not achieve total colon observation in all patients, though it is the gold standard of colon examination. Factors associated with incomplete CS have been reported in the literature: sex (female) \[[@bibr2-1756283X16673556]; [@bibr22-1756283X16673556]; [@bibr16-1756283X16673556]; [@bibr5-1756283X16673556]; [@bibr4-1756283X16673556]\], age (elderly) \[[@bibr22-1756283X16673556]; [@bibr1-1756283X16673556]; [@bibr16-1756283X16673556]; [@bibr5-1756283X16673556]\], previous abdominal or pelvic surgery \[[@bibr22-1756283X16673556]; [@bibr16-1756283X16673556]; [@bibr4-1756283X16673556]\], and diverticulum \[[@bibr5-1756283X16673556]\]. However, considering the characteristics of CCE, factors involved in difficulty in CCE excretion may differ from these factors. These factors should be investigated to understand whether the patient is suitable for CCE. If factors influencing complete CCE are clarified, patients in whom a CCE can be readily excreted can be selected; for such patients, the dose of a cleaning liquid can be reduced. It may be possible to establish order-made regimens appropriate for individual patients in the future. For patients in whom completion of the CCE procedure is difficult, and who do not wish to undergo CS, other colorectal examinations, such as CTC, may be adequately performed, and this may finally increase the proportion of patients undergoing CS.

The purpose of this study was to investigate clinical factors important to prospectively achieving completion of the CCE procedure and find CCE-matched patients.

Material and methods {#section6-1756283X16673556}
====================

Patients {#section7-1756283X16673556}
--------

We selected patients that were at least 20 years old, for whom a CCE was scheduled between June 2015 and February 2016, and from whom written informed consent regarding participation in this study was obtained, regardless of sex. We excluded patients with stenosis of the digestive tract, those definitively diagnosed with Crohn's disease, those who had undergone abdominal radiotherapy, those with pacemaker insertion, those with dysphagia, those with a history of hypersensitivity to drugs for examination, those in whom acute abdomen was suspected, those with spastic constipation, those with severely hard stools, and those with an electrolyte imbalance. The primary endpoint of this study was to prospectively clarify factors important to achieve completion of the CCE procedure. Its secondary endpoint was to clarify factors involved in the completion of a CCE within 4 h. The protocol of this study was approved by the Ethics Review Board of Nagoya University Hospital, Japan (2014-0255), and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000015277).

To patients for whom a CCE was scheduled, the purpose and contents of this study were explained, and informed consent was obtained. We took a blood test for checking the electrolyte imbalance related to the oral administration of several kinds of cleaning liquids and prokinetics. Prior to this study, a questionnaire survey of each patient's background regarding factors involved in entire colon observation was conducted. A pedometer (Lifecorder GS; Suzuken Co. Ltd, Nagoya, Japan) was attached to a waist belt immediately before examination. A CCE was performed according to the bowel preparation regimen presented in [Table 1](#table1-1756283X16673556){ref-type="table"}. This regimen is currently one of the Japanese standards because sodium phosphate (NaP) is not available in Japan. Polyethylene glycol (PEG) is frequently used as the main booster in Japan.

###### 

Schedule of bowel preparation used in the study.

![](10.1177_1756283X16673556-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Schedule                  Intake
  ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Day 2, before bedtime     2 Senna tablets, 12 mg each

  Day 1, all day            3 meals: low-fiber diet, sugar supplementation if necessary

   20:00                    Magnesium citrate 50 g (180 ml): hypertonic method

   Before bedtime           2 Senna tablets

  Day of examination        

   08:30                    1.5 l PEG

   10:00                    Capsule ingestion with mosapride citrate 20 mg. Attachment of a pedometer

   11:00                    Real-time monitoring

                            • If CCE remains in the stomach, additional examination should be conducted after 1 h. If it still remains in the stomach at that point, metoclopramide 10 mg should be intramuscularly injected.

                            • If it is present in the small intestine, the 1st booster should be started.

   1st boost (within 2 h)   Each patient drinks a mixture of PEG 1000 ml and water 1000 ml. Candies and gum are permitted.

                            • Real-time monitoring

                            The right colon or lumen seems to be dilated.

                            If the left colon or wall is reached, left abdominal compression (5 s × 5 sets)/using stairs/walking/postural changes/exercise to strengthen the abdominal muscles\* should be conducted.

                            →2nd boost

   2nd boost                Sodium picosulfate 48 mg

                            • Real-time monitoring (30 min after the completion of the 2nd boost)

                            The \* items should be performed. →3rd boost

   3rd boost\               Magnesium citrate 50 g (900 ml): isotonic method
  (within 1--2 h)           

                            If necessary, The \* items should be performed.

                            • Subsequently, additional drinks, light meals, irritating suppositories, enema, or the muscular injection of metoclopramide 10 mg should be decided after consultation with each patient.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCE, colon capsule endoscope; PEG, polyethylene glycol.

Definitions in this study {#section8-1756283X16673556}
-------------------------

'Non-CCE excretion' refers to cases in which a CCE is not excreted within the battery time, and does not mean retention of the capsule. Patients receiving any laxatives regularly, regardless of fecal property or frequency, were regarded as having 'constipation'. 'Previous abdominal surgery' refers to abdominal surgery without intestinal resection. In this study, there was no patient who had undergone intestinal resection. 'Abdominal symptoms' refer to the presence of symptoms, such as abdominal pain, distension or discomfort, for 3 days or more per month, within the past 3 months. Patients receiving drug therapy for diabetes regardless of HbA1c or those with an HbA1c of ⩾6.5% were regarded as having diabetes. The number of steps during examination and amount of water intake involving cleaning liquids were calculated every hour and reviewed in the analysis.

Colon cleansing level {#section9-1756283X16673556}
---------------------

In accordance with a previous article, we used 'excellent/good/fair/poor' to categorize the colon cleansing level \[[@bibr17-1756283X16673556]\]. 'Excellent/good' levels were evaluated as adequate, and 'fair/poor' as inadequate. We evaluated the colon cleansing level by dividing the colon into four segments: right colon (cecum, ascending colon), transverse colon, left colon (descending colon, sigmoid colon), and rectum.

Statistical analysis {#section10-1756283X16673556}
--------------------

All data were analyzed using SPSS version 23.0 statistical software (IBM, Tokyo, Japan). Logistic regression was used to estimate the hazard ratio (HR) and the 95% confidence interval (CI) of various factors associated with achieving completion of the CCE. Differences with values of *p* \< 0.05 were considered statistically significant.

Results {#section11-1756283X16673556}
=======

Patient characteristics {#section12-1756283X16673556}
-----------------------

During the study period, 70 patients were enrolled. This analysis was performed in 64 patients. Of the 6 that were excluded, 2 were excluded because the capsule could not reach the cecum within the examination time, 2 dropped out during examination because they were unable to take the amount of cleaning liquids, and 2 were excluded due to machinery problems.

Concerning the patient background, the mean age was 57.8 years, and the patients consisted of 36 males and 28 females, with a mean body mass index (BMI) of 22.7. The proportion of patients with constipation was 25.0%. Those who had undergone abdominal surgery accounted for 35.9%, those with abdominal symptoms accounted for 40.6%, those with diabetes accounted for 12.5%, and those with ulcerative colitis accounted for 15.6%. To assess the severity of comorbidity, we used Charlson comorbidity index \[[@bibr3-1756283X16673556]\], and the mean index was 0.66 ([Table 2](#table2-1756283X16673556){ref-type="table"}).

###### 

Patient characteristics.

![](10.1177_1756283X16673556-table2)

  -------------------------------- -------------------
  Number of patients               64
  Mean age (years)                 57.8 (25--87)
  Male/female                      36/28
  BMI (%)                          22.7 (16.2--31.6)
  Constipation (%)                 16 (25.0)
  Previous abdominal surgery (%)   23 (35.9)
  Abdominal symptoms (%)           26 (40.6)
  Diabetes (%)                     8 (12.5)
  Ulcerative colitis (%)           10 (15.6)
  Charlson comorbidity index       0.66 (0--4)
  -------------------------------- -------------------

BMI, body mass index.

CCE results {#section13-1756283X16673556}
-----------

With respect to the results of CCE, overall, the excretion rate (completed CCE rate) was 81.3% (52/64). The mean gastric transit time was 44.6 min, and the mean small intestinal transit time was 61.0 min \[[@bibr12-1756283X16673556]\]; shorter than conventional small intestinal capsule endoscopy. The mean colorectal transit time was 134.7 min, and the mean duration of all examinations was 355.5 min. Concerning the colon cleansing level, right colonic, transverse colonic, left colonic, and rectal levels were evaluated as adequate in 95.9%, 98.0%, 95.9%, and 89.8% of the patients, respectively. Patients with any findings accounted for 95.3%: diverticulum was observed in 62.5%, and colorectal polyps in 50.0%. There were no CCE-related adverse event, such as retention, or adverse reaction to cleansing liquids, such as nausea, vomiting or abdominal pain, in any patient. In the nonexcretion group, the final sites of CCE arrival were the left colon in 96.3% (11/12) of the patients and right colon in 8.7% (1/12). The mean total water intake was 3895.8 ml ([Table 3](#table3-1756283X16673556){ref-type="table"}).

###### 

Results of CCE procedure.

![](10.1177_1756283X16673556-table3)

  --------------------------------------------------------- ---------------------
  Number of excreted CCE (%)                                52 (81.3)
  Gastric transit time (min)                                44.6 (1--205)
  Small intestinal transit time (min)                       61.0 (6--177)
  Colorectal transit time (min)                             134.7 (3--529)
  Duration of examination (min)                             355.5 (75--999)
  Colon cleansing level                                     
  Adequate (%)                                              
   Right colon                                              95.9
    Transverse colon                                        98.0
   Left colon                                               95.9
   Rectum                                                   89.8
  Proportion of patients with findings (%)                  95.3
  Primary findings (%)                                      
    Diverticulum                                            62.5
    Colorectal polyp                                        50.0
   Erosion/flare                                            35.9
   Hemorrhoid                                               21.9
    Ulcerative colitis                                      15.6
  Adverse events (%)                                        0
  Final site of CCE arrival in the nonexcretion group (%)   
    Left colon                                              91.7
    Right colon                                             8.3
  Total water intake (ml)                                   3895.8 (2000--7700)
  --------------------------------------------------------- ---------------------

CCE, colon capsule endoscope.

Comparison of excretion and nonexcretion group {#section14-1756283X16673556}
----------------------------------------------

Factors that may influence excretion during a CCE were compared between the excretion and nonexcretion groups, as shown in [Table 4](#table4-1756283X16673556){ref-type="table"}. There were no significant differences in the age, sex, BMI, previous abdominal surgery, presence or absence of ulcerative colitis, Charlson comorbidity index, number of steps during examination, gastric transit time, small intestinal transit time, presence or absence of colorectal polyps, or presence or absence of diverticulum. There were significant differences for complete CCE excretion in the factors, constipation, abdominal symptoms, diabetes, and water intake during examination between the two groups.

###### 

Comparison of excretion and nonexcretion group.

![](10.1177_1756283X16673556-table4)

                                                   Excretion group      Nonexcretion group   *p* value
  ------------------------------------------------ -------------------- -------------------- ---------------------------------------------------------------
  Number of patients                               52                   12                   
  Mean age (years)                                 56.2 (25--84)        64.7 (39--87)        [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.121
  Male/female                                      32/20                4/8                  [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.108
  BMI                                              22.8 (16.2--31.6)    22.1 (17.2--27.3)    [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.705
  Constipation (%)                                 9 (17.3)             6 (50.0)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.016
  Previous abdominal surgery (%)                   17 (32.7)            6 (50.0)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.260
  Abdominal symptoms (%)                           18 (34.6)            8 (66.7)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.042
  Diabetes (%)                                     4 (7.7)              4 (33.3)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.015
  Ulcerative colitis (%)                           9 (17.3)             1 (8.3)              [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.440
  Charlson comorbidity index                       0.60 (0--4)          0.92 (0--2)          [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.231
  Number of steps during examination (steps/min)   9.46 (2.57--25.24)   6.63 (0.071--17.4)   [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.090
  Water intake during examination (ml/min)         13.6 (3.94--43.8)    6.45 (3.11--13.8)    [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}\<0.001
  Gastric transit time (min)                       44.4 (5--205)        45.6 (1--94)         [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.380
  Small intestinal transit time (min)              60.4 (6--177)        63.6 (21--132)       [\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.731
  Diverticulum                                     31 (59.6)            9 (75.0)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.258
  Colorectal polyp                                 26 (50.0)            6 (50.0)             [\*\*](#table-fn4-1756283X16673556){ref-type="table-fn"}0.625

Mann--Whitney test \*\*Fisher's exact method.

BMI, Body mass index.

Univariate and multivariate analyses using logistic regression {#section15-1756283X16673556}
--------------------------------------------------------------

The results of a review to clarify factors important to achieve completion of CCE are shown in [Table 5](#table5-1756283X16673556){ref-type="table"}. On univariate analysis, 4 factors were significantly associated with the excretion rate: the absence of constipation \[*p* = 0.022, odds ratio (OR): 4.778, 95% CI: 1.251--18.254\], absence of abdominal symptoms (*p* = 0.050, OR: 3.778, 95% CI: 1.000--14.273), a step count of ⩾5.0 per minute during examination (*p* = 0.034, OR: 4.200, 95% CI: 1.116--15.804), and a water intake of ⩾12.0 ml/min during examination (*p* = 0.015, OR: 13.870, 95% CI: 1.666--115.434). When performing multiple logistic analysis on all items, only a water intake of ⩾12.0 ml/min during examination (*p* = 0.025, OR: 46.753, 95% CI: 1.630--1341.248) was identified as an independent predictive factor.

###### 

Logistic analysis of factors influencing complete CCE.

![](10.1177_1756283X16673556-table5)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   Number of patients   Excreted (%)   Univariate analysis   Multivariate analysis           
  ------------------------------------------------ -------------------- -------------- --------------------- ----------------------- ------- -----------------------
  Age                                                                                  0.081                                                 

   ⩾65                                             23                   16 (69.6)                            0.317 (0.087--1.153)    0.158   0.151 (0.011--2.086)

   \<65                                            41                   36 (87.8)                            1.000                           

  Sex                                                                                  0.085                                                 

   Male                                            36                   32 (88.9)                            3.200\                  0.445   2.346 (0.263--20.884)
                                                                                                             (0.852--12.026)                 

   Female                                          28                   20 (71.4)                            1.000                           

  BMI                                                                                  0.838                                                 

   25⩽                                             12                   10 (83.3)                            1.190 (0.225--6.308)    0.409   5.937\
                                                                                                                                             (0.087--406.249)

   \<25                                            52                   42 (80.8)                            1.000                           

  Constipation                                                                         0.022                                                 

   Yes                                             15                   9 (60.0)                             1.000                   0.898   1.197 (0.076--18.779)

   No                                              49                   43 (87.8)                            4.778\                          
                                                                                                             (1.251--18.254)                 

  Previous abdominal surgery                                                           0.266                                                 

   Yes                                             23                   17 (73.9)                            0.486 (0.136--1.732)    0.526   0.461 (0.042--5.027)

   No                                              41                   35 (85.4)                            1.000                           

  Abdominal symptoms                                                                   0.050                                                 

   Yes                                             26                   18 (69.2)                            1.000                   0.197   4.220 (0.473--37.657)

   No                                              38                   34 (89.5)                            3.778\                          
                                                                                                             (1.000--14.273)                 

  Diabetes                                                                             0.026                                                 

   Yes                                             8                    4 (50.0)                             1.000                   0.149   30.015\
                                                                                                                                             (0.295--3054.065)

   No                                              56                   48 (85.7)                            6.000\                          
                                                                                                             (1.242--28.987)                 

  Ulcerative colitis                                                                   0.451                                                 

   Yes                                             10                   9 (90.0)                             2.302\                  0.864   0.750 (0.028--20.270)
                                                                                                             (0.263--20.155)                 

   No                                              54                   43 (79.6)                            1.000                           

  Charlson's comorbidity index                                                         0.266                                                 

   ⩾1                                              23                   17 (73.9)                            0.486 (0.136--1.732)    0.204   9.751\
                                                                                                                                             (0.291--327.046)

   0                                               41                   35 (85.4)                            1.000                           

  Number of steps during examination (steps/min)                                       0.034                                                 

   ⩾5.0                                            48                   42 (87.5)                            4.200\                  0.313   5.933\
                                                                                                             (1.116--15.804)                 (0.186--188.770)

   \<5.0                                           16                   10 (62.5)                            1.000                           

  Water intake during examination (mL/min)                                             0.015                                                 

   ⩾12.0                                           30                   29 (96.7)                            13.870\                 0.025   46.753\
                                                                                                             (1.666--115.434)                (1.630--1341.248)

   \<12.0                                          34                   23 (67.6)                            1.000                           

  Gastric transit time (min)                                                           0.201                                                 

   ⩾30                                             21                   19 (90.5)                            2.879\                  0.326   3.984 (0.253--62.676)
                                                                                                             (0.570--14.543)                 

   \<30                                            43                   33 (76.7)                            1.000                           

  Small intestinal transit time (min)                                                  0.718                                                 

   ⩾60                                             29                   23 (79.3)                            1.000                   0.255   0.277 (0.030--2.527)

   \<60                                            35                   29 (82.9)                            1.261 (0.359--4.432)            

  Diverticulum                                                                         0.327                                                 

   Yes                                             40                   31 (77.5)                            0.492 (0.119--2.034)    0.438   2.640 (0.227--30.638)

   No                                              24                   21 (87.5)                            1.000                           

  Colorectal polyp                                                                     1.000                                                 

   Yes                                             32                   26 (81.3)                            1.000 (0.285--3.509)    0.793   1.307 (0.177--9.627)

   No                                              32                   26 (81.3)                            1.000                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

The results of a review to clarify factors contributing to the completion of CCE within 4 h are shown in [Table 6](#table6-1756283X16673556){ref-type="table"}. On univariate analysis, four factors were significantly associated with CCE excretion within 4 h: the absence of constipation (*p* = 0.018, OR: 5.333, 95% CI: 1.334--21.325), ulcerative colitis (*p* = 0.044, OR: 5.391, 95% CI: 1.045--27.812), a water intake of ⩾12.0 ml/min during examination (*p* \> 0.001, OR: 10.679, 95% CI: 3.350--34.036), and a short intestinal transit time of \<60 min (*p* = 0.045, OR: 2.850, 95% CI: 1.026--7.916). When performing multiple logistic analysis in all items, a BMI of ⩾25 (*p* = 0.039, OR: 13.723, 95% CI: 1.135--165.913), the absence of constipation (*p* = 0.030, OR: 13.988, 95% CI: 1.287--152.047), and a water intake of ⩾12.0 ml/min during examination (*p* = 0.004, OR: 12.028, 95% CI: 2.225--65.029) were identified as independent predictive factors.

###### 

Logistic analysis of factors influencing complete CCE within 4 hours.

![](10.1177_1756283X16673556-table6)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   Number of patients   Achieved (%)   Univariate analysis   Multivariate analysis           
  ------------------------------------------------ -------------------- -------------- --------------------- ----------------------- ------- -------------------------
  Age                                                                                  0.942                                                 

   ⩾65                                             23                   11 (47.8)                            0.963 (0.346--2.674)    0.168   3.826 (0.567--25.807)

   \<65                                            41                   20 (48.8)                            1.000                           

  Sex                                                                                  0.198                                                 

   Male                                            36                   20 (55.6)                            1.932 (0.708--5.271)    0.538   0.564 (0.091--3.497)

   Female                                          28                   11 (39.3)                            1.000                           

  BMI                                                                                  0.169                                                 

   25⩽                                             12                   8 (66.7)                             2.522 (0.674--9.431)    0.039   13.723 (1.135--165.913)

   \<25                                            52                   23 (44.2)                            1.000                           

  Constipation                                                                         0.018                                                 

   Yes                                             15                   3 (20.0)                             1.000                   0.030   13.988\
                                                                                                                                             (1.287--152.047)

   No                                              49                   28 (57.1)                            5.333 (1.334--21.325)           

  Previous abdominal surgery                                                           0.942                                                 

   Yes                                             23                   11 (47.8)                            0.963 (0.346--2.674)    0.918   0.904 (0.132--6.199)

   No                                              41                   20 (48.8)                            1.000                           

  Abdominal symptoms                                                                   0.762                                                 

   Yes                                             26                   12 (46.2)                            1.000                   0.684   0.714 (0.141--3.608)

   No                                              38                   19 (50.0)                            1.167 (0.429--3.170)            

  Diabetes                                                                             0.173                                                 

   Yes                                             8                    2 (25.0)                             1.000                   0.256   4.500 (0.335--60.406)

   No                                              56                   29 (51.8)                            3.222 (0.598--17.358)           

  Ulcerative colitis                                                                   0.044                                                 

   Yes                                             10                   8 (80.0)                             5.391 (1.045--27.812)   0.065   18.129\
                                                                                                                                             (0.834--394.029)

   No                                              54                   23 (42.6)                            1.000                           

  Charlson's comorbidity index                                                         0.942                                                 

   ⩾1                                              23                   11 (47.8)                            0.963 (0.346--2.674)    0.981   1.023 (0.155--6.737)

   0                                               41                   20 (48.8)                            1.000                           

  Number of steps during examination (steps/min)                                       0.665                                                 

   ⩾5.0                                            48                   24 (50.0)                            1.286 (0.412-4.013)     0.427   0.414 (0.047-3.655)

   \<5.0                                           16                   7 (43.8)                             1.000                           

  Water intake during examination (mL/min)                                             \>0.001                                               

   ⩾12.0                                           30                   23 (76.7)                            10.679 (3.350-34.036)   0.004   12.028 (2.225-65.029)

   \<12.0                                          34                   8 (23.5)                             1.000                           

  Gastric transit time (min)                                                           0.332                                                 

   ⩾30                                             21                   12 (57.1)                            1.684 (0.587-4.828)     0.629   1.515 (0.282-8.141)

   \<30                                            43                   19 (44.2)                            1.000                           

  Small intestinal transit time (min)                                                  0.045                                                 

   ⩾60                                             29                   10 (34.5)                            1.000                   0.590   1.603 (0.288-8.940)

   \<60                                            35                   21 (60.0)                            2.850 (1.026-7.916)             

  Diverticulum                                                                         0.084                                                 

   Yes                                             40                   16 (40.0)                            0.400 (0.141-1.132)     0.656   0.665 (0.111-3.990)

   No                                              24                   15 (62.5)                            1.000                           

  Colorectal polyp                                                                     0.803                                                 

   Yes                                             32                   16 (50.0)                            1.133 (0.425-3.023)     0.731   1.307 (0.284-6.005)

   No                                              32                   15 (46.9)                            1.000                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#section16-1756283X16673556}
==========

The morbidity and mortality rates of colorectal cancer remain high. To prevent colorectal cancer development and colorectal cancer-related death, it may be important to positively undergo colorectal examination. The sensitivity and specificity of second-generation CCE for detecting colorectal polyps measuring ⩾6 mm is 63--91% and 64--94%, respectively; this procedure proves to be useful \[[@bibr27-1756283X16673556], [@bibr28-1756283X16673556], [@bibr24-1756283X16673556]; [@bibr7-1756283X16673556]; [@bibr11-1756283X16673556]\]. On the other hand, several issues to be clinically resolved have been raised. In particular, the most important issue is that the entire colon observation rate (excretion rate, completed CCE rate) is not 100%. One idea for improving completed CCE rates was to identify the patients most suitable for CCE. Therefore, we conducted a prospective study to clarify factors important to achieve completion of CCE ([Table 5](#table5-1756283X16673556){ref-type="table"}).

Water intake per hour during examination was identified as an independent predictive factor important to achieve completion of CCE. This suggests that if water is not ingested at a specific speed or faster, it is not effective in achieving completion of CCE. PEG solution, which was used in this study, is isotonic, and does not cause any colonic membrane-mediated changes \[[@bibr15-1756283X16673556]\]. Briefly, the oral administration of PEG solution at a specific speed or faster and intestinal retention of water involving PEG solution, may be important for CCE excretion. To achieve a complete CCE, it may also be important to select the patients who can drink enough cleansing liquids at a satisfactory speed.

Factors associated with incomplete CS, sex (female), age (elderly), previous abdominal or pelvic surgery, and diverticulum have been indicated, but, of these, no factor was identified as a factor that makes CCE excretion difficult, though both CS and CCE belong to the category of colorectal examination. One reason was that we could understand the relationship between constipation and late CCE excretion, since constipation patients have a long, spastic or very relaxed colon. Another reason was speculated that water intake during CCE significantly affected the completion of CCE with a high OR and therefore the other factors could not affect it. Our results provide useful information for selecting the colorectal examinations; for those with factors associated with incomplete CS, such as sex (female), age (elderly), previous abdominal or pelvic surgery, and diverticulum, CCE may be positively recommended, because these factors do not make CCE excretion difficult. For those who are unable to drink a sufficient volume of water, involving cleansing liquids, CS should be selected rather than CCE. For those who refuse CS despite the above conditions, appropriate examinations, such as CTC, may be selected with reference to the individuals' characteristics.

We also reviewed factors excreting the capsule within 4 h ([Table 6](#table6-1756283X16673556){ref-type="table"}). A BMI of ⩾25, the absence of constipation, and enough water intake during examination were identified as independent predictive factors.

Constipation affected CCE excretion time. We defined constipation as the status of the patient who used any laxative regularly. When selecting CCE, the regular use of laxative should be ascertained prior to examination.

A BMI of ⩾25 as an independent predictive factor reflects that a CCE is more readily excreted in patients with a higher abdominal and visceral fat level. A study reported lower BMI as a factor associated with incomplete CS \[[@bibr2-1756283X16673556]\], suggesting that abdominal wall and visceral fat prevents loop formation on colonoscope insertion, facilitating endoscope insertion in the obese patient. There may also be similar mechanism in CCE. In patients with a BMI ⩾ 25, that is, obese patients, visceral fat-related abdominal pressure may always be loaded on the intestinal tract in comparison with thin patients. This abdominal pressure can contribute to early CCE excretion. In this study, the capsule was left in the left colon, especially the sigmoid colon, in most patients in whom a CCE was not excreted out of the body. In such patients, real-time monitoring or imaging showed flexions of the sigmoid colon for a long duration. This may have been related to curvatures, and the flexions may have made it impossible for the capsule to go through the sigmoid colon. A study reviewed CTC findings in patients with incomplete CS, and indicated the length of the colon, that of the transverse colon, that of the sigmoid colon, number of curvatures, and diverticulum as factors associated with incomplete CS \[[@bibr10-1756283X16673556]\]. The number of sigmoid colon curvatures should be examined in the future. Furthermore, another study investigated the length, maximal diameter, and surface area of the intestinal tract through enema, and reported that the maximal diameter of the sigmoid colon was the second shortest, following that of the descending colon, and that the length and surface area of the sigmoid colon were the second longest and largest, following those of the transverse colon \[[@bibr19-1756283X16673556]\].

A main limitation of this study was the types of boosters. Boosters were the important factors to achieve completion of the CCE. NaP and sodium sulfate (Suprep) were not used in this regimen. Although NaP and Suprep are useful as a booster \[[@bibr28-1756283X16673556]; [@bibr23-1756283X16673556]\], they are not available in Japan; PEG is mainly used as a booster in Japan. Nevertheless, a paper reports that PEG has been proven to have a poor effect as a booster \[[@bibr28-1756283X16673556]\]. PEG acts as a booster due to a cascade effect, whereas other boosters can act through an activation of colonic movements. With the NaP and Suprep regimen, it will be necessary to review examination-related factors along with the number of steps and water intake during examination. Furthermore, the number of patients, which was relatively small despite being a prospective study, also had limitations. The target sample size on the trial registry was 100 patients; however we analyzed the data of 70 patients and obtained significant results, and so patient recruitment was stopped. In the future, a larger number of patients should be investigated by using other regimens.

In conclusion, the completion of CCE was most closely related to water intake per hour in regimens including PEG as a booster. In addition, excretion-accelerating factors included a high BMI and the absence of constipation. However, the results of this study cannot be directly translated to regimens of preparations containing different boosters.
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